CVE-2023-30615

Improper Neutralization of Script-Related HTML Tags in a Web Page (Basic XSS) in iris-web

Description

Iris is a web collaborative platform aiming to help incident responders sharing technical details during investigations. A stored Cross-Site Scripting (XSS) vulnerability has been identified in iris-web, affecting multiple locations . The vulnerability in allows an attacker to inject malicious scripts into the application, which are then executed when a user visits the affected locations. This can lead to unauthorized access, data theft, or other malicious activities. An attacker need to be authenticated on the application to exploit this vulnerability. The issue was patched in version 2.2.1 of iris-web.

Categories

6.3
CVSS
Severity: Medium
CVSS 3.1 •
EPSS 0.54%
Vendor Advisory github.com
Affected: dfir-iris iris-web
Published at:
Updated at:

References

Frequently Asked Questions

What is the severity of CVE-2023-30615?
CVE-2023-30615 has been scored as a medium severity vulnerability.
How to fix CVE-2023-30615?
To fix CVE-2023-30615, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2023-30615 being actively exploited in the wild?
As for now, there are no information to confirm that CVE-2023-30615 is being actively exploited. According to its EPSS score, there is a ~1% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
What software or system is affected by CVE-2023-30615?
CVE-2023-30615 affects dfir-iris iris-web.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.